10.1016/0163-7258(94)00048-4
10.1016/S1063-5823(03)01013-5
10.1152/ajpcell.00001.2005
10.1016/j.coph.2004.01.010
10.1016/j.brainresrev.2004.12.005
10.1177/00220345010800021501
10.1016/S0306-4522(03)00523-2
1997, Scand J Urol Nephrol Suppl, 184, 77
2002, Scand J Urol Nephrol Suppl, 210, 72
10.1016/j.brainres.2004.10.048
10.1016/S0006-8993(03)03365-1
10.1113/jphysiol.2002.028373
2002, J Neurosci, 22, 8139, 10.1523/JNEUROSCI.22-18-08139.2002
10.1016/j.jacc.2005.03.073
10.1016/S0735-1097(00)00813-5
1985, Clin Cardiol, 8, 460, 10.1002/clc.4960080903
10.1002/(SICI)1522-2683(19990701)20:10<2059::AID-ELPS2059>3.0.CO;2-T
10.1016/S0736-5748(01)00048-X
10.1113/jphysiol.2003.044172
10.1016/j.brainresrev.2004.12.004
2005, Am J Physiol, 289, F489
10.1152/ajprenal.00118.2004
2003, Am J Physiol, 284, H619
10.1016/S0165-6147(02)00045-7
10.1152/ajpcell.00238.2002
10.1016/0304-3959(77)90066-5
2005, Curr Opin Investig Drugs, 6, 275
10.1016/S0091-3057(98)00244-5
10.1016/S0003-4975(03)00008-0
10.1046/j.1365-2680.2001.00235.x
10.1523/JNEUROSCI.2660-04.2004
2000, Exp Opin Ther Patents, 10, 1169
10.1111/j.0953-816X.2004.03325.x
2000, Am J Respir Cell Mol Biol, 23, 52, 10.1165/ajrcmb.23.1.3936
10.1080/0953710042000260164
10.1016/j.ijdevneu.2004.09.003
10.1113/jphysiol.2003.056697
2000, Mol Pharmacol, 58, 1502, 10.1124/mol.58.6.1502
1972, Pharmacol Rev, 24, 509
Burnstock G (1978) A basis for distinguishing two types of purinergic receptor, in Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach (Straub RW and Bolis L eds) pp 107-118, Raven Press, New York.
10.1016/0753-3322(89)90161-3
10.1002/(SICI)1098-2299(199611/12)39:3/4<204::AID-DDR2>3.0.CO;2-V
10.1016/S0140-6736(96)91082-X
10.1046/j.1469-7580.1999.19430335.x
2001, Handbook of Experimental Pharmacology, Purinergic and Pyrimidinergic Signalling I—Molecular, Nervous and Urinogenitary System Function, 151, 89
2001, Handbook of Experimental Pharmacology, Purinergic and Pyrimidinergic Signalling II—Cardiovascular, Respiratory, Immune, Metabolic and Gastrointestinal Tract Function, 151, 141
10.1016/S0165-6147(00)01643-6
2001, Handbook of Experimental Pharmacology, Purinergic and Pyrimidinergic Signalling I—Molecular, Nervous and Urinogenitary System Function, 151, 423
10.1016/S1063-5823(03)01001-9
10.1016/S1063-5823(03)01010-X
10.1016/j.coph.2003.08.001
10.1111/j.1476-5381.1970.tb10646.x
10.1016/0306-3623(85)90001-1
10.1016/S0074-7696(04)40002-3
10.1016/S1566-0702(02)00005-X
10.1016/0007-1226(94)90136-8
2000, J Pharmacol Exp Ther, 295, 862
10.1016/S0959-4388(96)80060-2
10.1046/j.1523-1747.2003.12050.x
10.1046/j.1526-4637.2001.002001015.x
10.1007/s10143-002-0233-x
2004, Anticancer Research, 24, 2853
10.1016/j.bcp.2004.06.026
10.1016/S0306-4522(03)00228-8
10.1016/j.nbd.2004.09.001
10.1016/j.canlet.2004.05.023
10.1002/(SICI)1098-1136(199804)22:4<360::AID-GLIA5>3.0.CO;2-7
2003, J Biomed Sci, 10, 725, 10.1007/BF02256324
10.1016/j.pain.2005.01.002
2000, Pharmacol Rev, 53, 553
10.1111/j.1471-4159.2004.02699.x
1993, J Pharmacol Exp Ther, 266, 160
1996, J Neurosci, 16, 2495, 10.1523/JNEUROSCI.16-08-02495.1996
10.1046/j.0953-816x.2001.01714.x
10.1016/S0006-2952(00)00465-2
10.1111/1523-1747.ep12606228
2005, Bone, 36, 418, 10.1016/j.bone.2004.10.016
10.1016/S0303-7207(03)00003-0
10.1111/j.1365-2141.2004.04976.x
10.1152/ajpcell.00605.2002
2004, Am J Physiol, 287, R1164
10.1016/S0304-3940(02)00385-3
10.1046/j.1523-1747.2002.19505.x
10.1002/(SICI)1098-2299(199811/12)45:3/4<207::AID-DDR18>3.3.CO;2-E
2000, Drug Dev Res, 49, 187, 10.1002/(SICI)1098-2299(200003)49:3<187::AID-DDR9>3.0.CO;2-F
2004, Am J Physiol, 287, G417
10.1113/jphysiol.1929.sp002608
1993, Am J Physiol, 265, C577, 10.1152/ajpcell.1993.265.3.C577
10.4049/jimmunol.169.1.15
10.1016/S0960-9822(00)00436-X
10.1016/S0301-0082(01)00005-3
1998, Thromb Haemost, 80, 867, 10.1055/s-0037-1615378
10.1016/S0162-0134(01)00171-4
10.4049/jimmunol.167.6.3300
10.4049/jimmunol.173.12.7539
10.1002/(SICI)1098-2299(199611/12)39:3/4<333::AID-DDR14>3.0.CO;2-2
10.1016/S1063-5823(03)01012-3
10.1016/0165-6147(96)81593-8
10.1111/j.1469-7793.1997.503bb.x
1994, Am J Physiol, 267, C886, 10.1152/ajpcell.1994.267.4.C886
10.1016/S0166-2236(00)01674-X
10.1126/science.298.5593.556
10.1016/0092-8674(95)90445-X
10.1016/S0306-4522(02)00397-4
10.1161/01.CIR.0000085073.69189.88
2002, Curr Opin Investig Drugs, 3, 69
1994, Pharmacol Rev, 46, 143
10.1146/annurev.pharmtox.45.120403.095731
10.1016/j.urology.2003.10.031
10.1016/S0304-3940(99)00776-4
10.1016/S0306-4522(02)00190-2
1997, J Neurosci, 17, 6325, 10.1523/JNEUROSCI.17-16-06325.1997
1986, Am Rev Respir Dis, 134, 1140
2001, Thromb Haemost, 86, 222, 10.1055/s-0037-1616220
10.1016/j.cub.2004.03.002
10.1016/S1471-4892(02)00212-6
10.1359/jbmr.2001.16.5.846
10.1007/s00441-004-0979-2
10.1046/j.1471-4159.2003.01995.x
10.1523/JNEUROSCI.4019-03.2004
10.1016/S0028-3908(02)00294-0
10.1016/j.brainres.2005.02.081
2002, Am J Physiol, 282, C75, 10.1152/ajpcell.2002.282.1.C75
10.1113/jphysiol.2003.045294
2004, Front Biosci, 9, 1011, 10.2741/1301
Gourine AV and Spyer KM (2003) Chemosensitivity of medullary respiratory neurones: a role for ionotropic P2x and GABAA receptors, in Chemoreception (Gonzalez G, Prabhakar JM, Pequignot JM, Nurse CA and Dalmaz Y eds) pp 375-387, Kluwer Academic/Plenum Publishers, New York.
10.1097/00002281-200305000-00021
10.4049/jimmunol.174.12.7725
10.1111/j.0906-6705.2003.00110.x
10.1046/j.1523-1747.2003.12379.x
10.1046/j.1523-1747.2003.12261.x
2005, Neuroscience, 132, 199
10.1016/j.jneuroim.2005.03.007
10.1111/j.1469-7793.2001.00437.x
Han WJ, Kim SY, and Lee YB (2004) Neuroprotective effect of extracellular ATP-induced interleukin-10 expression in an in vitro model of brain ischemia, in 2004 Abstract Viewer/Itinerary Planner; Program no. 100.1. Society for Neuroscience, Washington, DC.
10.1097/00003246-199202000-00015
10.1016/S0022-5347(05)64632-0
10.1016/0145-2126(94)90046-9
2004, Oncol Rep, 12, 1139
10.1016/j.jvs.2003.05.001
10.1016/j.ultrasmedbio.2005.04.017
2003, Chem Senses, 28, A110
2003, J Neurosci, 23, 8291, 10.1523/JNEUROSCI.23-23-08291.2003
1993, Br J Pharmacol, 109, 183, 10.1111/j.1476-5381.1993.tb13551.x
10.1016/j.bbrc.2004.07.148
10.1016/S0165-6147(03)00123-8
10.1016/S0014-2999(01)01319-X
10.1016/S0304-3959(01)00434-1
2002, Am J Physiol, 282, H784
10.1016/S0024-3205(99)00353-7
10.1046/j.1440-1681.2000.03314.x
10.1097/00007890-200009270-00003
10.1007/s11302-005-6210-4
Jackson EK (2001) P1 and P2 receptors in the renal system, in Purinergic and Pyrimidinergic Signalling II: Cardiovascular, Respiratory, Immune, Metabolic and Gastrointestinal Tract Function (Abbracchio MP and Williams M eds) pp 33-71, Springer-Verlag, Berlin.
1977, Acta Otolaryngol, 83, 195, 10.3109/00016487709128833
10.1016/S0014-2999(02)01756-9
2001, J Neurosci, 21, 4134, 10.1523/JNEUROSCI.21-12-04134.2001
10.1161/01.HYP.0000121881.77212.b1
10.1016/0895-7061(96)00287-7
Jun D and Kim K (2004) ATP-mediated necrotic volume increase (NVI) in substantia nigra pars compacta dopaminergic neuron, 2004 Abstract Viewer/Itinerary Planner; Program no. 222.18. Society for Neuroscience, Washington, DC.
1997, Acta Physiol Scand, 160, 283, 10.1046/j.1365-201X.1997.00143.x
10.1016/S1566-0702(02)00257-6
10.1046/j.1365-2044.2003.02960.x
2000, J Neurosci, 20, 8868, 10.1523/JNEUROSCI.20-23-08868.2000
2000, Panminerva Med, 42, 11
10.1016/S0169-409X(02)00154-0
1997, J Physiol (Lond), 498, 709, 10.1113/jphysiol.1997.sp021895
2003, J Neurosci, 23, 7426, 10.1523/JNEUROSCI.23-19-07426.2003
10.1213/00000539-198702001-00103
1996, J Neurochem, 66, 604, 10.1046/j.1471-4159.1996.66020604.x
2001, Am J Physiol, 280, G787
2005, Am J Physiol, 288, F1032
2001, Am J Physiol, 281, H2198
10.1016/S0014-2999(00)00731-7
2002, Am J Physiol, 282, F281
Knutsen LJS and Murray TF (1997) Adenosine and ATP in epilepsy, in Purinergic Approaches in Experimental Therapeutics (Jacobson KA and Jarvis MF eds) pp 423-447, Wiley-Liss, New York.
10.1016/S0024-3205(02)02410-4
2005, Drug News Perspect, 18, 1
2003, Am J Cardiol, 92, 26
10.1111/j.1471-4159.2004.02885.x
2004, Cell Tissue Res, 317, 117
10.1097/00042307-200307000-00004
10.4049/jimmunol.167.6.3308
10.1016/S1074-7613(00)80364-7
10.1016/S1471-4892(02)00225-4
10.1046/j.1365-2745.2003.01620.x
1997, Am J Physiol, 273, C679, 10.1152/ajpcell.1997.273.2.C679
10.1182/blood-2004-03-0834
10.1016/0026-0495(94)90203-8
1999, Curr Pharm Des, 5, 1029, 10.2174/1381612805666230112212126
10.1016/j.brainres.2003.09.070
10.1016/j.brainres.2005.01.076
10.1007/s00011-004-1248-2
10.1002/1529-0131(199802)41:2<246::AID-ART8>3.0.CO;2-I
Loubatières-Mariani MM, Hillaire-Buys D, Chapal J, Bertrand G, and Petit P (1997) P2 purinoceptor agonists: new insulin secretagogues potentially useful in the treatment of non-insulin-dependent diabetes mellitus, in Purinergic Approaches in Experimental Therapeutics (Jacobson KA and Jarvis MF eds) pp 253-260, Wiley-Liss, New York
Lu SH, Fraser MO, Chancellor MB, Cheng CL, and de Groat WC (2002) Voiding dysfunction and purinergic mechanisms in awake chronic spinal cord injured (SCI) rats, in 2004 Abstract Viewer/Itinerary Planner; Program no. 68.6. Society for Neuroscience, Washington, DC.
10.1007/s00441-004-0906-6
2002, Investig Ophthalmol Vis Sci, 43, 3555
10.1016/j.micinf.2003.09.017
10.1177/107602960300900204
10.1016/j.brainres.2004.03.001
10.1097/01.CCM.0000098026.12020.45
10.1016/S0024-3205(01)01231-0
10.1016/j.neuroscience.2004.03.031
10.1046/j.1523-1747.2003.12558.x
10.1111/j.1365-2133.2004.05768.x
1994, J Neurosci, 14, 6992, 10.1523/JNEUROSCI.14-11-06992.1994
10.1016/j.neuint.2003.11.017
10.1111/j.1469-7793.2001.t01-1-00115.x
1994, Jpn J Pharmacol, 66, 445, 10.1254/jjp.66.445
2003, J Neurosci, 23, 6058, 10.1523/JNEUROSCI.23-14-06058.2003
10.1016/S1090-3801(02)00096-4
10.1095/biolreprod.103.026054
2001, Acta Otolaryngol, 121, 10, 10.1080/000164801300006209-1
10.1016/S0306-4522(02)00804-7
10.1076/ceyr.21.4.782.5550
2004, Toxicology, 197, 177
2003, Intensive Care Med, 29, 10, 10.1007/s00134-002-1550-9
10.1042/0264-6021:3580001
10.3109/15419060109080747
10.1007/s11064-004-6876-y
2003, J Neurosci, 23, 2348, 10.1523/JNEUROSCI.23-06-02348.2003
1999, Prog Brain Res, 120, 323, 10.1016/S0079-6123(08)63566-9
1974, Circ Res, 34, 455, 10.1161/01.RES.34.4.455
2004, Anat Rec, 280A, 884, 10.1002/ar.a.20093
2003, J Neurosci, 23, 1659, 10.1523/JNEUROSCI.23-05-01659.2003
10.1111/j.1460-9568.2004.03508.x
2002, Am J Physiol, 283, R273, 10.1152/ajpcell.00514.2001
10.1113/jphysiol.2003.048587
10.1016/j.autneu.2004.04.003
10.1016/S0006-8993(03)03028-2
2002, Am J Physiol, 282, F10
10.1016/S0022-5347(05)65403-1
2002, J Neurosci, 22, 8363, 10.1523/JNEUROSCI.22-19-08363.2002
10.1007/s00441-005-1114-8
10.1016/S0896-6273(03)00760-8
10.1097/00045391-200203000-00008
10.1111/j.1526-4610.2004.04011.x
Pintor J (2000) Purinergic signalling in the eye. in Nervous Control of the Eye (Burnstock G and Sillito A eds) pp 171-210, Harwood Academic Publishers, London.
10.1111/j.1475-1313.2004.00182.x
10.1016/j.thromres.2004.06.021
10.1016/S1566-0702(02)00179-0
10.1128/IAI.68.9.4930-4937.2000
1998, Pharmacol Rev, 50, 413
10.1358/dnp.2003.16.3.876886
10.1016/j.eururo.2005.04.019
10.1016/S0301-0082(99)00017-9
10.1016/S0021-9150(01)00681-5
2003, Clin Sci (Lond), 104, 467, 10.1042/CS20030053
10.1161/01.RES.86.12.1211
2003, J Orofac Pain, 17, 245
10.1016/S0301-0082(02)00155-7
2003, J Trauma, 55, 290, 10.1097/01.TA.0000078882.11919.AF
2005, J Soc Gynecol Investig, 12, P363A
10.1016/S1566-0702(00)00284-8
2004, Neuropharmacology, 47, 1093, 10.1016/j.neuropharm.2004.08.003
10.1111/j.1469-7793.2000.00891.x
10.1113/jphysiol.2001.013469
10.1046/j.1523-1755.2002.00621.x
10.1007/s00418-003-0579-3
1991, J Rheumatol, 18, 716
10.4049/jimmunol.164.9.4893
10.4049/jimmunol.171.10.5442
10.1016/S0301-0082(03)00050-9
1998, Eur J Biochem, 252, 147, 10.1046/j.1432-1327.1998.2520147.x
10.1182/blood-2002-12-3745
10.1016/j.bbrc.2004.06.179
10.1016/S1063-5823(03)01002-0
2002, Am J Physiol, 282, F763
10.1046/j.1440-1681.2001.03404.x
Shabbir M, Thompson CS, Mikhailidis DP, Morgan RJ, and Burnstock G (2003) Extracellular ATP attenuates the growth of hormone refractory prostate cancer in vivo, in 5th World Congress of Urological Research; 2003 Sep 24-27; Kensington, London, UK.
Shields CB, Zhang YP, Chen S, Han Y, Shields LBE, Chiang B, Burke DA, and Haskins R (2004) Treatment of spinal cord injury via topical perfusion with an ATP solution, in 2004 Abstract Viewer/Itinerary Planner; Program no. 418.8. Society for Neuroscience, Washington, DC.. Program no. 418.8.
10.1016/j.pain.2005.03.042
2005, Am J Physiol, 288, F1243
1999, J Immunol, 163, 558, 10.4049/jimmunol.163.2.558
10.1111/j.1476-5381.1992.tb14408.x
10.1016/j.expneurol.2004.05.027
10.1152/japplphysiol.01405.2004
10.1016/j.micpath.2004.01.004
10.1016/j.urology.2004.06.073
2001, Am J Physiol, 280, C1431, 10.1152/ajpcell.2001.280.6.C1431
10.1111/j.1523-1755.2005.00152.x
1998, Lab Investig, 78, 1375
10.1177/09680519990050010501
10.1034/j.1399-6576.2000.440903.x
10.1016/j.bbrc.2003.12.164
10.1016/S0304-3940(03)00082-X
10.1016/S1063-5823(03)01008-1
2001, Exp Biol Med (Maywood), 226, 434, 10.1177/153537020122600507
10.1016/S0896-6273(02)01067-X
10.4049/jimmunol.166.10.6276
10.1016/S0169-409X(03)00105-4
Stutts MJ and Boucher RC (1999) Cystic fibrosis gene and functions of CFTR implications of dysfunctional ion transport for pulmonary pathogenesis, in Cystic Fibrosis in Adults (Yankaskas JR and Knowles MR eds) pp 3-25, Lippincott-Raven, Philadelphia.
10.1016/S0378-5955(03)00221-1
2004, ORL J Otorhinolaryngol Relat Spec, 66, 80, 10.1159/000077800
10.1016/0022-4804(85)90058-7
1984, Am J Physiol, 247, R1047
10.1046/j.1464-410X.2002.02912.x
1998, Horm Metab Res, 30, 323, 10.1055/s-2007-978892
2001, Scand J Gastroenterol, 36, 459, 10.1080/00365520121151
2004, J Endocrinol, 37, 305
10.1111/j.1464-410X.2004.04858.x
10.1016/S0008-6363(01)00542-9
10.1016/j.mehy.2004.04.018
10.1016/j.tins.2004.12.002
10.1097/00001756-200106130-00036
2000, J Neurosci, 20, RC90, 10.1523/JNEUROSCI.20-15-j0007.2000
Turner C, Tam FWK, Lai P-C, Tarzi RM, Burnstock G, Pusey CD, Cook HT, and Unwin R (2004b) Glomerular expression of the ATP-sensitive P2X7 receptor is increased in proliferative glomerulonephritis (Abstract). Society of Nephrology, Renal Week; 2004 Oct 27-Nov 1; St. Louis, MO.
10.1177/10454411990100020701
10.1358/dnp.2003.16.9.829343
10.1113/jphysiol.2003.060079
2002, Histochem Cell Biol, 118, 193, 10.1007/s00418-002-0447-6
2003, Cell Tissue Res, 312, 149, 10.1007/s00441-003-0716-2
10.1016/S0143-4160(03)00024-1
2001, Physiol Rev, 81, 767, 10.1152/physrev.2001.81.2.767
10.1046/j.1528-1157.43.s.5.26.x
10.1016/S0006-8993(03)02769-0
1998, Mol Pharmacol, 53, 969
2001, J Neurosci, 21, 5670, 10.1523/JNEUROSCI.21-15-05670.2001
10.1016/S0028-3908(99)00034-9
10.1111/j.1523-1755.2004.00717.x
10.1007/s11302-005-6314-x
10.1016/S0306-4522(01)00377-3
2003, Neurology, 61, S9, 10.1212/WNL.61.8_suppl_4.S9
10.1016/0049-0172(89)90050-4
10.1097/00001756-200305060-00008
10.1161/01.ATV.0000080350.37408.5A
2004, Gastroenterology, 126, 75
10.1016/j.canlet.2004.11.027
10.1007/s00441-005-1149-x
10.1016/j.jpain.2003.09.006
10.1046/j.1442-2042.10.s1.11.x
2004, Am J Physiol, 287, G647
10.1016/j.gastro.2003.07.008
10.1016/S0378-5955(98)00208-1
2004, Histochem Cell Biol, 122, 111
10.1007/s00418-004-0620-1
10.1016/j.plefa.2003.08.016
10.1016/j.pharmthera.2004.10.007
Yamada T and Chakrabarty AM (2004) ATP-utilizing enzymes, purinergic recerptor modulation, cupredoxins and mammalian cell death, in Pseudomonas (Ramos J-L ed) pp 47-67, Kluwer Academic, New York.
10.1016/S0304-3940(02)00175-1
2004, Am J Physiol, 287, H1096
10.1016/S0306-4522(03)00435-4
10.1046/j.1365-2982.2001.00276.x
10.1016/S0531-5565(00)00175-3
Yu Y and de Groat WC (2004) Sensitization of pelvic afferent nerves in the in vitro urinary bladder—pelvic nerve preparation of the rat by purinergic agonists or by cyclophosphamide (CYP) pre-treatment, in 2004 Abstract Viewer/Itinerary Planner; Program no. 541.3. Society for Neuroscience, Washington, DC.
10.1016/j.bmcl.2004.11.044
10.1016/S0896-6273(03)00717-7
10.1152/ajpcell.00158.2004
10.1016/j.leukres.2004.04.001
2000, Am J Physiol, 278, L726
10.1016/S0006-8993(01)02512-4
10.1016/S0006-8993(00)02781-5